Myraquat

Foundation date

14/04/2020

Sector

#Biotechnology - Therapeutics

Subsector

Therapeutic areas

Myraquat develops therapeutic compounds acting as membrane modulators to control pathogenic microorganisms.

Upcoming events

Latest news

  • argenx announces VYVGART (efgartigimod alfa) authorized for sale by Health Canada for generalized myasthenia gravis

    Thursday September 21st 2023

  • Galapagos appoints Simon Sturge to its Board of Directors

    Tuesday September 19th 2023

  • 13th Investment for HERAN Partners: Broken String Biosciences (UK)

    Tuesday September 19th 2023